Education
About Us
Working with TipRanks
Follow Us
Esperion Therapeutics (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
$3.55
-$0.02(-0.92%)
At close: 4:00 PM EST
$3.55
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $4.18
Previous CloseN/A
Volume1.55M
Average Volume (3M)5.10M
Market Cap
$810.43M
Enterprise Value$1.18B
Total Cash (Recent Filing)$92.45M
Total Debt (Recent Filing)$600.99M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Feb 24, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding239,063,430
10 Day Avg. Volume4,749,263
30 Day Avg. Volume5,103,652
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.06
Price to Sales (P/S)1.24
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue3.88
Enterprise Value/Gross Profit7.24
Enterprise Value/Ebitda-43.10
Forecast
1Y Price Target
$7.94Price Target Upside123.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.09
Revenue Forecast (FY)$380.09M
Bulls Say, Bears Say
Bulls Say
Clinical GuidelinesInclusion of bempedoic acid as the only new non-statin recommended therapy in European dyslipidemia guidelines strengthens clinical validation and supports wider prescriber adoption.
ExclusivitySettlement agreements and an ANDA arrangement that secure U.S. market exclusivity for Nexletol and Nexlizet through 2040 reduce near-term generic threats and help protect the revenue runway.
International CommercializationRegulatory approvals and partner-led launches in key markets, including Japan, expand global availability and create potential milestone and royalty income tied to partner sales.
Bears Say
Competitive PressureA rapidly evolving competitive landscape, including next-generation PCSK9 entrants and mixed prescriber feedback, suggests bempedoic acid may remain a niche product and face challenges capturing broad market share.
Regulatory HurdlesHealth Canada’s notice of non-compliance for NEXLIZET related to chemistry and manufacturing controls risks delaying Canadian commercialization and limiting market access.
Sales PerformanceReported quarterly sales for Nexletol and Nexlizet that came in below consensus put downward pressure on valuation and raise questions about the pace of commercial growth.
Esperion News
ESPR FAQ
What was Esperion Therapeutics’s price range in the past 12 months?
Esperion Therapeutics lowest stock price was $0.69 and its highest was $4.17 in the past 12 months.
What is Esperion Therapeutics’s market cap?
Esperion Therapeutics’s market cap is $810.43M.
When is Esperion Therapeutics’s upcoming earnings report date?
Esperion Therapeutics’s upcoming earnings report date is Feb 24, 2026 which is in 24 days.
How were Esperion Therapeutics’s earnings last quarter?
Esperion Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.078 by -$0.082.
Is Esperion Therapeutics overvalued?
According to Wall Street analysts Esperion Therapeutics’s price is currently Undervalued.
Does Esperion Therapeutics pay dividends?
Esperion Therapeutics does not currently pay dividends.
What is Esperion Therapeutics’s EPS estimate?
Esperion Therapeutics’s EPS estimate is 0.29.
How many shares outstanding does Esperion Therapeutics have?
Esperion Therapeutics has 239,063,430 shares outstanding.
What happened to Esperion Therapeutics’s price movement after its last earnings report?
Esperion Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.078. Following the earnings report the stock price went down -14.966%.
Which hedge fund is a major shareholder of Esperion Therapeutics?
Currently, no hedge funds are holding shares in ESPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.94 (123.66% Upside)
$7.94 (123.66% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $232.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.89%
Trailing 12-Months
Company Description
Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth, successful strategic initiatives, and international expansion. However, increased operating expenses and onetime financial impacts were noted as challenges. Overall, the highlights of growth and strategic progress outweigh the lowlights.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$7.94
▲(123.66% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
10.49% Mutual Funds
0.02% Other Institutional Investors
76.59% Public Companies and
Individual Investors